Spots Global Cancer Trial Database for mylotarg
Every month we try and update this database with for mylotarg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | NCT00195000 | Acute Myeloid L... Myelodysplastic... | Mylotarg Cytarabine | 60 Years - | Weill Medical College of Cornell University | |
| Vyxeos for Induction of Low- or Intermediate-risk. | NCT05599360 | Leukemia, Myelo... | Vyxeos Mylotarg | 18 Years - 70 Years | Shaare Zedek Medical Center | |
| Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | NCT00038831 | Acute Myelogeno... Myelodysplastic... Chronic Lymphoc... | Mylotarg Fludarabine Melphalan Anti-thymocyte ... Stem cell trans... | 12 Years - 75 Years | M.D. Anderson Cancer Center | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | NCT00882102 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia | NCT00304447 | Leukemia, Myelo... Infusions, Intr... | Mylotarg | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | NCT00968071 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab Ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | NCT04849910 | Leukemia, Myelo... Myelodysplastic... | VOR33 Mylotarg | 18 Years - 70 Years | Vor Biopharma | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | NCT00968071 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab Ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment | NCT01698879 | Novo Acute Myel... | Mylotarg | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
